Browse studies

Find your next paid study

158 recruiting studies matching your filters

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and chi…

Estimated

~$10 – $8,750

Relay Therapeutics, Inc.NCT06789913

Phase 1

A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin…

Acute Myeloid LeukemiaAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05886049

Phase 2

Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS

This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome th…

Acute Myeloid Leukemia With Gene MutationsMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT04493164

Phase 1

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute m…

AMLAML With Mutated NPM1Hematologic Malignancy+9 more

Estimated

~$10 – $8,750

Kura Oncology, Inc.NCT06001788

Phase 2

Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance

Background: Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs beco…

Insulin Receptor MutationPartial Lipodystrophy

Estimated

~$10 – $5,625

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT05470504

Phase 1

A Pilot Study of Duffy Null-Specific Dose Modifications for Individuals With Duffy Null Phenotype Receiving Standard of Care Systemic Anti-Cancer Therapies

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null spec…

Multiple MyelomaTriple Negative Breast CancerDuffy Blood Group, Chemokine Receptor Gene Mutation+1 more

Estimated

~$10 – $7,500

Andrew Hantel, MDNCT07341867

Phase 1

Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma

This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treati…

EGFR Gene MutationGlioblastomaMGMT-Unmethylated Glioblastoma+1 more

Estimated

~$10 – $7,500

Hideho Okada, MD, PhDNCT06186401

Phase 1

An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to near…

Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation

A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced …

TP53 Y220C MutationAdvanced Solid Tumors

Estimated

~$10 – $8,750

PMV Pharmaceuticals, IncNCT07372625

A Multicenter Screening Study to Characterize the Prevalence of the KIT D816V Mutation in Patients With Suspected Clonal Mast Cell Disease

This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.

Clonal Mast Cell DiseaseKIT D816V MutationSuspected KITD816V Mutated Clonal Mast Cell Disease

Estimated

~$10 – $1,050

Blueprint Medicines CorporationNCT07143669

Phase 1

A Phase 1/2, Open-Label, Multicenter Trial With a Single Ascending Dose Cohort With Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tolerability, and Efficacy of DB-OTO in Children and Infants With Biallelic hOTOF Mutations

Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat pediatric and adult par…

Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT05788536

Observational

Patient Centered Education About Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy: a Pilot Randomized Controlled Trial

The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical…

BRCA1 MutationBRCA2 Mutation

Estimated

~$10 – $6,250

Duke UniversityNCT06972719